Piramal moves to commercialize amyloid tracer in Korea

Kathy Mahdoubi | | Health Imaging | Molecular Imaging

The PET amyloid imaging agent florbetaben F-18 may soon be available in South Korea as a result of a licensing agreement and partnership between producer Piramal Imaging and Ci-Co Healthcare, according to a Nov. 21 announcement from Piramal.

Ci-Co, as strategic partner and agent, will be charged with obtaining authorization to commercialize and market the radiotracer from the Korean Health Authorities. Manufacturing and supply are planned with South Korean radiopharmacy network DuChemBio.

"Piramal Imaging is committed to building a global presence in nuclear medicine and making florbetaben F-18 available to patients around the world. Ci-Co Healthcare shares Piramal Imaging's dedication and we look forward to a strong partnership that will allow both companies to achieve its goals," said Piramal board member Ludger Dinkelborg, in a release.

Kathy Mahdoubi

Related Content

Repurposed radiotracer lights up treatment-resistant tumors 'like a Christmas tree'
Researchers receive grant worth millions to develop portable PET scanner
Why is the US still dependent on foreign medical isotope production?
Downed high-flux reactor could restart sooner than anticipated
Some nuc med departments are already feeling the strain of the isotope shortage
NorthStar opens facility to assist with development and distribution of vital radioisotopes

Around the web

Radiology Business
The biggest challenges facing radiology business managers in 2025

RBMA President Peter Moffatt discusses some of the biggest obstacles facing the specialty in the new year. 

Cardiovascular Business
New cardiac prevention paradigm explored in TRANSFORM trial using AI and CCTA

Deepak Bhatt, MD, director of the Mount Sinai Fuster Heart Hospital and principal investigator of the TRANSFORM trial, explains an emerging technique for cardiac screening: combining coronary CT angiography with artificial intelligence for plaque analysis to create an approach similar to mammography.

Cardiovascular Business
Cardiology practices pay $17.7M to settle fraud allegations brought on by whistleblowers

A total of 16 cardiology practices from 12 states settled with the DOJ to resolve allegations they overbilled Medicare for imaging agents used to diagnose cardiovascular disease.